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Abstract
Purpose—Prior studies suggest a need for greater clarity about provider roles in team-based 
cancer care. However, little is known about patient’s preferences for which providers handle their 
care needs after primary cancer treatment.
Methods—We surveyed women newly diagnosed with stages 0-II breast cancer who were treated 
in 2014–15 as reported to the Georgia and Los Angeles SEER registries (N=2,372, 68% response 
rate). Patient preferences for which provider handles the following care needs after treatment were 
ascertained: follow-up mammograms, screening for other cancers, general preventive care, and 
comorbidity management. The associations between patient demographic factors with preferences 
for provider roles (Oncology-directed care vs. primary care provider (PCP)-directed) were 
assessed using multivariable logistic regression.
Results—The majority of women preferred that their PCPs handle their general preventive care 
(79%) and comorbidity care (84%), but a notable minority of women preferred their oncologists 
direct this care (21% and 16%). Minority women (black and Asian vs. white) and women with a 
high school education or less (vs. college grad or more) had a greater odds of preferring oncology-
directed care (vs. PCP-directed) for their general preventive care (black OR: 2.01, 95%CI: 1.43, 
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2.82; Asian OR: 1.74, 95%CI: 1.13, 2.69; ≤ high school OR: 1.51, 95%CI: 1.10, 2.08). Similar 
variation existed for comorbidity care.
Conclusion—In this sample, minority women and those with less education more often 
preferred oncologists direct aspects of their care after breast cancer treatment that are normally 
delivered by a PCP. Efforts to clarify provider roles in survivorship care to patients may be 
effective in improving team-based cancer care.
INTRODUCTION
The exponential growth in the aging adult cancer survivor population1 necessitates the 
delivery of comprehensive, coordinated continuing care after the initial course of treatment. 
Indeed, the National Academy of Medicine recommends team-based continuing care that 
promotes cross-specialty provider collaboration, particularly between primary care 
physicians (PCPs) and oncologists.2 However, coordination and communication between 
primary care and oncology care teams remains challenging, in part due to the lack of clarity 
around provider roles in delivering survivorship care.3 Current survivorship guidelines 
suggest that patients with favorable long-term prognosis can be transitioned back to primary 
care after completion of initial curative treatment and the PCPs role in survivorship care can 
be enhanced.4–6 Though, the guidelines do not explicitly state which provider should handle 
the numerous aspects of survivorship care.
Prior research has largely focused on identifying provider-level barriers to providing team-
based cancer care, including knowledge deficits about survivorship care and differences in 
practices and attitudes about provider roles in this care among both PCPs and 
oncologists.7–11 However, very little is known about patient preferences and expectations 
regarding which providers deliver the various aspects of survivorship care after primary 
treatment. In order to deliver continuing care that is patient-centered, it is critical to 
understand how patients perceive provider roles in delivering continuing cancer care and 
whether these preferences vary across patients. Understanding these patient preferences, 
particularly early in the transition to survivorship, is important as this is a critical time to 
discuss the goals of survivorship care and coordinate this care going forward. This may be 
particularly important in underserved populations who have historically had difficulty in 
access to care.12,13 While team-based care models offer promise for improving continuing 
care, our ability to design interventions to promote patient-centered, comprehensive, team-
based cancer care will be limited without a better understanding of the preferences and 
expectations of patients themselves.
The objectives of this study were to examine patient preferences for provider roles in follow-
up care after primary breast cancer treatment and whether preferences vary by patient 
demographics in a large, contemporary, diverse, population-based sample of women with 
favorable prognosis breast cancer.
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As described previously,14 the Individualized Cancer Care (iCanCare) Study is a large, 
diverse, population-based survey study of women with early-stage breast cancer and their 
providers. We identified and accrued 3930 women, ages 20–79 with newly diagnosed, early-
stage breast cancer (stages 0-II) as reported to the SEER registries of Georgia and Los 
Angeles County in 2014–15. Patients were ineligible if they had tumors larger than 5cm, had 
4 or more positive nodes, or could not complete a questionnaire in English or Spanish (N= 
258). Of the remaining 3,672 eligible women who were mailed surveys, 2,502 completed the 
survey (68% response rate) and those who identified having a PCP at the time of survey 
(N=2,372) were included in this analysis.
Patients were identified via rapid case ascertainment of their initial surgical pathology 
reports, derived from a list of “definitive” surgical procedures (performed with the intent of 
removing the entire tumor and obtaining clear margins, including excisional biopsy). They 
were then surveyed after definitive surgery (average 8 months after diagnosis) about their 
treatment experiences, knowledge and attitudes, appraisal of communication and decision-
making, and quality of life. To encourage response, we provided a $20 cash incentive and 
used a modified Dillman approach to patient recruitment,15 including reminders to non-
respondents. All materials were sent in English and Spanish to those with Spanish surnames. 
Responses to the survey were then merged with clinical data by the SEER registries and a 
de-identified analytic dataset was created. The study was approved by the University of 
Michigan Institutional Review Board.
Measures
As described previously,14 questionnaire content was developed based on a conceptual 
framework, research questions, hypotheses, prior literature and our prior work. We utilized 
standard techniques to assess content validity, including systematic review by design 
experts, cognitive pretesting with patients, and pilot studies in selected clinic populations.
Patient preferences for Provider Roles in Follow-up Care
We asked respondents to indicate their preferences regarding the role of oncologists and 
PCPs in delivering four aspects of their survivorship care: follow-up for breast cancer 
(mammograms), screening for other cancers, general preventive care (vaccinations, check-
ups) and treatment for ongoing or future medical conditions (such as diabetes, heart disease). 
Specifically, we asked, “After your initial cancer treatment is finished, which doctor would 
you prefer to see for each of the following?”, with possible response categories that included 
“Prefer primary care provider”, “Prefer cancer doctor” (i.e., oncologist), “Either one is fine”, 
or “Prefer to see both” for each of the four aspects of care. These responses were mutually 
exclusive and categorized as PCP-directed vs. Oncology-directed (Oncology/Both/Either) 
for analysis. We performed multiple sensitivity analyses to confirm the robustness of the 
findings across different specifications of the outcome variable. These included defining the 
outcome as the original four-level response variable categorized as PCP (referent), 
Oncologist, Both and Either and re-categorizing the outcome as PCP vs. Oncology/Both, 
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with Either excluded. All of the sensitivity analyses performed using these outcome 
definitions yielded comparable results.
Demographics
Demographic factors were collected via survey and included age at diagnosis and race, 
categorized as white, black, Latina, Asian, and other/unknown. We also collected 
information on educational attainment (>high school, high school graduate or some college 
or more) and insurance status (Private, Medicare, Medicaid, Other Public, None).
Covariates
The covariates in this analysis included clinical and breast cancer treatment factors, 
measures of PCP continuity and frequency, and patient-reported worry about recurrence. 
Clinical factors included the number of comorbid conditions (COPD, heart disease, diabetes 
or stroke), breast cancer treatment characteristics, including primary surgical treatment 
modality (lumpectomy, unilateral mastectomy, bilateral mastectomy), use of chemotherapy 
(yes/no) and endocrine therapy (yes/no). To ascertain primary care continuity, respondents 
were asked, “How long have you been seeing your primary care provider?” with response 
categories of < 6 months, 6–11 months, 1–2 years and more than 2 years, which were 
collapsed into < 1 year, 1–2 years and > 2 years for analyses. Patients were also asked 
““How many times have you seen your PCP since your cancer diagnosis?”, which was 
categorized as 0, 1, 2 or 3+. Frequency of worry about recurrence was defined by asking 
women to indicate on a 5 point scale how often they worried about their cancer coming back 
in the past month (not at all to always) and was then dichotomized as frequent worry 
(sometimes/often/almost always) vs. less worry (almost never/rarely).
Statistical Analysis
The overall distribution (weighted %) of patient preferences for PCP-directed vs. Oncology-
directed care for each of the four aspects of care (mammograms, screening for other cancers, 
comorbidity, preventive services) were estimated. The bivariate distributions of patient 
preferences for PCP-directed vs. Oncology-directed care were then compared across age, 
race, and education for each of the four aspects of follow-up care using Rao-Scott Chi-
Square tests.
The covariate-adjusted associations between patient-level demographics (age, race, 
education, insurance) and patient preferences for Oncology-directed care were then 
estimated using logistic regression for each individual aspect of follow-up care, adjusting for 
time from diagnosis to survey completion, study site, comorbidity, surgical treatment, 
chemotherapy, radiation therapy, endocrine therapy, worry about recurrence and PCP 
frequency and continuity. PCP-directed was treated as the consistent referent category across 
models, as this is an early-stage population where fully transitioning back to primary care is 
likely appropriate.
All statistical analyses incorporated weights to allow our statistical inference more 
representative of the target population and reduce potential bias due to non-response. This 
included the use of design weights to account for differential probability of sample selection 
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and non-response weights to account for disproportionate non-response rates across different 
patient subgroups.14,16,17 All analyses were performed using SAS 9.4 (Cary, NC), used two-
sided tests, and p-values <0.05 were considered statistically significant.
RESULTS
Table 1 shows the demographic and clinical characteristics of the sample of 2,372 women 
included in this analysis. The majority of women were over the age of 60 (63%) and were 
White (54%), followed by Black (18%), Latina (15%), and Asian (10%). Forty-five percent 
had private insurance and 39% had a college education or more. Over a quarter had at least 
one other comorbid condition (30%). The majority of women received a lumpectomy (63%), 
26% received chemotherapy, 60% received radiation therapy, and 68% had initiated 
endocrine therapy at the time of survey. Over a third of women (36%) reported frequently 
worrying about breast cancer recurrence. The majority of women (67%) reported seeing 
their PCP for more than 2 years and 73% having at least 1 visit with their PCP on average 
since their diagnosis. (Table 1)
Patient preferences for provider roles for general preventive care, comorbidity care, 
mammography, and screening for other cancers are displayed in Figure 1. For general 
preventive and comorbidity care, the majority of women preferred their PCPs handle these 
services (79% and 84%), but notable percentages of women preferred their oncologists 
handle these services (21% and 16%). The vast majority of women reported they prefer their 
oncologists handle their mammography (93%) and second cancer screening (91%) rather 
than their PCP. (Figure 1)
For general preventive care and comorbidity care, while the majority of women preferred 
PCP-directed care, variation existed across race and education as displayed in Table 2. For 
both service types, there was significant variation in provider preference across race: Asian 
women were most likely to report this preference for both preventive care (29%) and 
comorbidity care (23%), followed by Latina women (28% and 23%), black women (28% 
and 21%) and white women (15% and 11%) (p<0.001). A greater proportion of women with 
high school degree or less preferred their oncologists handle these services when compared 
to women with a college degree or more education (p<0.001). (Table 2)
For mammography and second cancer screenings, the majority of women preferred their 
oncologists direct this care rather than their PCPs, but there was less variation across age, 
race and education as also displayed in Table 2. For mammography, the proportion of 
women who preferred their oncologists handle this care decreased slightly with age 
(p=0.06), with 96% of those less than 50 years old reporting this preference compared to 
92% of those over age 70. A greater proportion of women with a college degree or more 
preferred their oncologists direct this care when compared to women with a high school 
degree or less (95% vs. 92%) (p=0.002). For second cancer screenings, no significant 
variation existed across age, race, education or insurance. (Table 2)
Figure 2 A–D displays the covariate-adjusted associations between patient 
sociodemographic characteristics (age, race, education, insurance) and patient-reported 
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preferences for provider roles in follow-up care, comparing a preference for oncology-
directed vs. PCP-directed care for each of the four aspects of follow-up care. For general 
preventive care (Figure 2A), the odds of black and Asian women reporting a preference that 
their oncologists handle this care rather than their PCPs were significantly greater than the 
odds of white women reporting this preference (Black OR: 2.00, 95%CI: 1.43, 2.82, Asian 
OR: 1.95, 95%CI: 1.28, 2.97). The odds of women with a high school education or less 
preferring their oncologists handle their preventive care rather than their PCPs were 1.53 
times the odds of women with a college degree or more reporting this preference (Adjusted 
OR: 1.53, 95%CI: 1.12, 2.11). (Figure 2A) For comorbidity care (Figure 2B), black women 
were again more likely to prefer their oncologists handle this care rather than their PCPs 
when compared to white women (black OR: 1.93, 95%CI: 1.34, 2.79). (Figure 2B) Women 
with less than a high school education were more likely to prefer their oncologists handle 
their comorbidity care when compared to women with a college degree or more (OR: 1.50, 
95%CI: 1.06, 2.12). (Figure 2B) Women with private or other insurance were less likely to 
prefer their oncologists handle their comorbidity care when compared to women with 
Medicaid insurance (OR: 0.56, 95%CI: 0.36–0.85). The full multivariable-adjusted results 
for all covariates are shown in the Supplemental Online Table.
For mammography (Figure 2C), there were no significant differences in the odds of women 
preferring their oncologists vs. their PCPs across levels of race or age. (Figure 2C) However, 
lower educational attainment was associated with a greater odds of reporting preferences for 
PCP-directed care (vs. oncology-directed) when compared to women with a college 
education or more (Some college OR: 0.49, 95%CI: 0.31, 0.77; <High school graduate OR: 
0.63, 95%CI: 0.39,1.02). For screening for other cancers (Figure 2D), the odds that black 
women preferred their oncologists handle this service rather than their PCPs were nearly 
twice the odds among white women (black OR: 1.96, 95%CI: 1.15, 3.36). No significant 
differences in preferences for second cancer screenings were seen across age, education or 
insurance. (Figure 2D)
DISCUSSION
Results from this population-based study of early-stage breast cancer patients suggest that 
women have clear preferences for which providers they want to handle their survivorship 
care after primary treatment. Of note, a substantial minority of women in this study 
preferred that their oncologists handle aspects of survivorship care that are typically 
delivered in a primary care setting. These results suggest that patients may benefit from 
better education about provider roles and specifically, the potential benefits of greater 
involvement of the PCP, in delivering care after primary breast cancer treatment. Differences 
by race and education in preferences suggest additional challenges for those seeking to 
extend the model of PCP-led care to diverse populations of breast cancer survivors.
Our findings that the majority of women preferred to see their oncologists for services 
typically considered related to the cancer - mammography and second cancer screenings - 
are not surprising, but suggest there is an opportunity to educate patients about PCPs’ ability 
to manage these care needs. Additionally, the findings that some women, particularly 
minority women and those with less education, prefer to see their oncologists for their 
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general preventive and comorbidity care, are notable, as PCPs typically direct this care. If 
women are reluctant to go to their PCPs for these services, they may be at greater risk of 
receiving fragmented survivorship care or not receiving the preventive care they need as they 
age. In addition, as survivorship care is complex, protracted, and often includes competing 
care priorities with other conditions, the involvement of PCPs is important as they are often 
the providers most attuned to patients’ preferences and may be best able to prioritize 
competing care needs.10 PCPs are often already involved throughout the cancer care 
continuum,2 and, interestingly, our prior work in this cohort suggests that their involvement 
during treatment may be greatest among minority women and those with less education.14 
As such, it is important that clinicians discuss provider roles with patients and encourage 
them to continue their relationship with their PCP throughout the continuum of their cancer. 
These discussions are particularly critical to have with patients early in the transition from 
primary treatment to survivorship when the goals of survivorship care are typically first 
discussed. Also, targeting these sub-populations of women to understand their concerns and 
clarify provider roles and the potential benefits of PCP leadership may be particularly 
effective for interventions focused on improving the delivery and quality of team-based 
cancer care.
Adult cancer patients with favorable prognoses, like those included in this study, most will 
now live long after their diagnosis and are more likely to die of causes other than their 
cancer.18–21 This also argues for the increased involvement of PCPs, to ensure that 
comprehensive care focusing on more than just the cancer is delivered. However, prior 
studies which are mostly qualitative, suggest that some cancer patients may be hesitant and 
uncertain about the role of the PCP in delivering this care.22–25 As a result, many survivors 
report that they continue to receive care and reassurance from their cancer specialists rather 
than their PCPs.22 Further compounding this issue, current survivorship guidelines do not 
specify how roles should be shared among primary care and oncology care teams.5,6 
Therefore, uncertainty remains among PCPs and oncologists as well about who should be 
handling the different aspects of survivorship care.7,26 Future versions of survivorship 
guidelines and care plans should therefore consider including additional clarification around 
provider roles in delivering the various aspects of survivorship care. Additionally, ensuring 
that PCPs have the training and resources they need to effectively care for cancer patients is 
increasingly important.
While this study has a number of strengths, including the use of a large, diverse, population-
based sample of women and being one of the first to provide insight into patients preferences 
for which provider manages the specific aspects of their follow-up care, there are potential 
limitations. The ascertainment of preferences for follow-up care occurred on average 8 
months after diagnosis when many women have not yet fully started focusing on their 
survivorship care. Therefore, it is possible that the timing relative to completing treatment 
may have influenced womens’ preferences for provider roles and it remains unknown 
whether these preferences change as time from diagnosis increases. We did, however, adjust 
for the timing of survey completion in our models to account for the influence of any 
variation in time from diagnosis to survey completion on our results, and found the results 
did not change. As our population only includes breast cancer patients in Los Angeles 
County and Georgia, generalizability to other populations may be limited. Finally, we did 
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not have information on which provider ultimately handled each aspect of care, and 
therefore future research should assess how these preferences align with the actual 
utilization of these services in survivorship.
CONCLUSIONS
Most women with early-stage breast cancer reported clear preferences regarding which 
providers handle the various aspects of their continuing care after breast cancer treatment. 
While many women preferred PCPs handle their general preventive care, many did not 
identify PCPs as their preferred providers for cancer screening and surveillance, suggesting 
a need for both patient and provider education about the ability of PCPs to deliver this care. 
Efforts to clarify provider roles to patients, and in particular, the roles of PCPs in cancer 
survivorship care, may improve team-based cancer care, satisfaction, and outcomes.
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Patient Preferences for Provider Roles in Survivorship Care (weighted %). *Of the 2372 
women, 79 were missing preferences for mammography, 89 were missing second cancer 
screening, 82 were missing preventive care and 85 were missing comorbidity preferences. 
**For mammography, 12.6% responded “Either” and 18.6% responded “Both”. For second 
cancer screenings, 12.0% responded “Either” and 14.5% responded “Both”. For preventive 
care, 8.0% and 7.0% responded “Either” or “Both” and for comorbidity care, 5.4% and 6.8% 
responded “Either” or “Both”. “Either” and “Both” were combined with those who 
responded “Oncologist” into the “Oncologist-directed” category for analyses.
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A–B: Covariate-adjusted ORs and 95% CIs Comparing Patient Preferences for Provider 
Roles in General Preventive Care (A) and Comorbidity Care (B). ORs were obtained from 
the logistic regression, which include the following covariates: age, race, education, 
insurance, comorbidities, treatment, time from diagnosis to survey, radiation treatment, 
chemotherapy treatment, endocrine therapy, PCP frequency, PCP continuity, and worry 
about recurrence, and site.
Figure 2A footnote: 286 women out of 2,372 were excluded from the model due to missing 
values.
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Figure 2B footnote: 290 women out of 2372 were excluded from the model due to missing 
values.
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A–B: Covariate-adjusted ORs and 95% CIs Comparing Patient Preferences for Provider 
Roles in Mammography (A) and Second Cancer Screenings (B). ORs were obtained from 
the logistic regression, which include the following covariates: age, race, education, 
insurance, comorbidities, treatment, time from diagnosis to survey, radiation treatment, 
chemotherapy treatment, endocrine therapy, PCP frequency, PCP continuity, and worry 
about recurrence, and site.
Figure 3A footnote: 290 of the 2372 women were excluded from the model due to missing 
values.
Wallner et al. Page 15













Figure 3B footnote: 290 of the 2372 women were excluded from the model due to missing 
values.
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Table 1
Patient demographic and clinical characteristics (n=2,372)














Medicare or VA 27
Private or other 46
None/missing 16
Education
≤ High School Degree 29
Some College 29
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Haven’t seen PCP since diagnosis 25
1 visit 25
2 visits 21
3 or more visits 27
PCP Continuity
< 6 months 9
6–11 months 9
1–2 years 13




Time from diagnosis to survey (in months) – Mean (SD) 8.30 (3.54)
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